112 result(s) have been found!
| Accession | Name | Sequence | Source/Organism | Mechanism | Assay Type | Cell Line | Cancer Type | Activity |
|---|---|---|---|---|---|---|---|---|
| dbacp00770 | A specific Eps8/EGFR Inhibitor Peptide 327 | EFLDCFQKF | A specific Eps8/EGFR Inhibitor Peptide 327 | Immune response to tumor cell recognition | Lactate dehydrogenase (LDH)-release assay | PC-3 | Pancreatic cancer | IC50 : 83.44 ± 4.62 μM |
| dbacp01180 | Apo E | LRVRLASHLRKLRKRLLRDADDLQKRLAVY | Apoprotein E | Cell membrane disintegration | MTT/MTS assay | PANC-1 | Pancreatic cancer | 55 % Cytotoxity at 40 µg/ml |
| dbacp01181 | Apo E | LRVRLASHLRKLRKRLLRDADDLQKRLAVY | Apoprotein E | Cell membrane disintegration | MTT/MTS assay | Paca-2 | Pancreatic cancer | 55 % Cytotoxity at 40 µg/ml |
| dbacp01608 | Bim | EIWIAQELRRIGDEFNAYYAR | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Panc-02 | Pancreatic cancer | Not found |
| dbacp02317 | Cationic Amphiphilic | GIIKKIIIKKIIIKKIIIKKI | AMP | Membrane disruption | WST-1 assay | HeLa | Pancreatic cancer | IC50 : 4 µM |
| dbacp02318 | Cationic Amphiphilic | GIIKKIIIKKI | AMP | Membrane disruption | WST-1 assay | HL-60 | Pancreatic cancer | IC50 : >500 µM |
| dbacp02319 | Cationic Amphiphilic | GIIKKIIIKKIIIKKI | AMP | Membrane disruption | WST-1 assay | HL-60 | Pancreatic cancer | IC50 : 25 µM |
| dbacp02320 | Cationic Amphiphilic | GIIKKIIIKKIIIKKIIIKKI | AMP | Membrane disruption | WST-1 assay | HL-60 | Pancreatic cancer | IC50 : 10 µM |
| dbacp02467 | ChBac3.4 | RFRLPFRRPPIRIHPPPFYPPFRRFL | Goat | Cell necrosis; Inhibiting processes of protein synthesis; Damaging the mitochondrial membrane | TUNEL assay, Reactive oxygen intermediates (ROS) assay | Not specified | Pancreatic cancer | Not found |
| dbacp02690 | Dermaseptin-PH | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay, Lactate dehydrogenase (LDH) assay | PANC-1 | Pancreatic cancer | IC50 : 17.44 - 49.51 μM |
| dbacp02695 | Dermaseptin-PH (DRS-PH) | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | MCF-7 | pancreatic cancer | IC50 : 7.44 μM |
| dbacp02700 | Dermaseptin-PH (DRS-PH) | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | U251MG | Pancreatic cancer | IC50 : 49.51 μM |
| dbacp02705 | Dermaseptin-PH (DRS-PH) | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | H157 | Pancreatic cancer | IC50 : 25.51 μM |
| dbacp02710 | Dermaseptin-PH (DRS-PH) | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | PC-3 | Pancreatic cancer | IC50 : 21.78 μM |
| dbacp02715 | Dermaseptin-PH (DRS-PH) | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | PANC-1 | Pancreatic cancer | IC50 : 28.95 μM |
| dbacp02720 | Dermaseptin-PH (DRS-PH) | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | HMEC-1 | Pancreatic cancer | IC50 : 51.04 μM |
| dbacp02733 | Dermaseptin-PT9 | GLWSKIKDAAKTAGKAALGFVNEMV | Brownbelly leaf frog | Disruption of cell membranes | MTT assay, Lactate dehydrogenase (LDH) assay | PANC-1 | Pancreatic cancer | IC50 : 8.64 - 18.51 μM |
| dbacp02738 | Dermaseptin-PT9 | GLWSKIKDAAKTAGKAALGFVNEMV | Skin secretion, Brownbelly leaf frog, Purchased in Peru, South America | Disruption of cell membranes | MTT assay, Lactate dehydrogenase (LDH) assay | PANC-1 | Pancreatic cancer | IC50 : 8.64 - 18.51 μM |
| dbacp02777 | Disintegrin metalloproteinase/disintegrin echistatin | IGIAYNRGMCDPKKSVGTVMDHSTEHLSVAVAMAHEMGHNLGMDHDGNQCNCGGAGCVMSEELIESRSYKFSDCSKNQYQNYLTIYKPQCILNQPLRTDTVSTPVSGNELLQNSANPCYDPLTCHPREGEQCESGPCCRNCKFLKEGTICKRARGDDMDDYCNGKTCDCPRNPHKGPATAKGSVLM | Saw-scaled viper | Membrane-disruption | Transwell migration assay | U373MG | Pancreatic cancer | IC50 : 5.7 μM |
| dbacp03319 | hP1 | HSHRDFQPVLHLVALNSPLSGGMRG | Human endostatin peptides | Anti-angiogenesis | Matrigel assay | BxPC-3 | Pancreatic cancer | 39% inhibition at 7 mg/kg/d |
| dbacp03320 | hP2 | MRGIRGADFQAFQQARAVGLAGTFR | Human endostatin peptides | Anti-angiogenesis | Matrigel assay | BxPC-3 | Pancreatic cancer | 19% inhibition at 7 mg/kg/d |
| dbacp03321 | hP3 | TFRAFLSSRLQDLYSIVRRADRAAV | Human endostatin peptides | Anti-angiogenesis | Matrigel assay | BxPC-3 | Pancreatic cancer | No inhibition at 7 mg/kg/d |
| dbacp03322 | hP4 | AAVPIVNLKDELLFPSWEALFSGSE | Human endostatin peptides | Anti-angiogenesis | Matrigel assay | BxPC-3 | Pancreatic cancer | No inhibition at 7 mg/kg/d |
| dbacp03323 | hP5 | GSEGPLKPGARIFSFDGKDVLRHPT | Human endostatin peptides | Anti-angiogenesis | Matrigel assay | BxPC-3 | Pancreatic cancer | 29% inhibition at 7 mg/kg/d |
| dbacp03324 | hP6 | HPTWPQKSVWHGSDPNGRRLTESY | Human endostatin peptides | Anti-angiogenesis | Matrigel assay | BxPC-3 | Pancreatic cancer | No inhibition at 7 mg/kg/d |
| dbacp03325 | hP7 | ETWRTEAPSATGQASSLLGGRLLGQ | Human endostatin peptides | Anti-angiogenesis | Matrigel assay | BxPC-3 | Pancreatic cancer | No inhibition at 7 mg/kg/d |
| dbacp03326 | hP8 | LGQSAASAHHAYIVLAIENSFMTASKKK | Human endostatin peptides | Anti-angiogenesis | Matrigel assay | BxPC-3 | Pancreatic cancer | No inhibition at 7 mg/kg/d |
| dbacp03373 | IL-4Rα-lytic hybrid peptide | KQLIRFLKRLDRNGGGKLlLKlLkkLLKlLKKK | Interleukin-4 receptor a (IL-4Ra) chain | Induction of apoptosis | WST-1 assay | BXPC-3 | Pancreatic cancer | IC50 : 6.8 µMol/L |
| dbacp03374 | IL-4Rα-lytic hybrid peptide | KQLIRFLKRLDRNGGGKLlLKlLkkLLKlLKKK | Interleukin-4 receptor a (IL-4Ra) chain | Induction of apoptosis | WST-1 assay | SU.86.86 | Pancreatic cancer | IC50 : 7.5 µMol/L |
| dbacp03487 | K8, 23-DPT9 | MDILKKSKFLILFLGVVSLSICKEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | MCF-7 | Pancreatic cancer | IC50 : 8.64μM |
| dbacp03492 | K8, 23-DPT9 | MDILKKSKFLILFLGVVSLSICKEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | U251MG | Pancreatic cancer | IC50 : 18.51μM |
| dbacp03497 | K8, 23-DPT9 | MDILKKSKFLILFLGVVSLSICKEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | H157 | Pancreatic cancer | IC50 : 9.88μM |
| dbacp03502 | K8, 23-DPT9 | MDILKKSKFLILFLGVVSLSICKEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | PC-3 | Pancreatic cancer | IC50 : 9.97μM |
| dbacp03507 | K8, 23-DPT9 | MDILKKSKFLILFLGVVSLSICKEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | PANC-1 | Pancreatic cancer | IC50 : 11.17μM |
| dbacp03512 | K8, 23-DPT9 | MDILKKSKFLILFLGVVSLSICKEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | HMEC-1 | Pancreatic cancer | IC50 : 48.80μM |
| dbacp04347 | Lytic | KLlLKlLkkLLKlLKKK | Interleukin-4 receptor a (IL-4Ra) chain | Induction of apoptosis | WST-1 assay | BXPC-3 | Pancreatic cancer | IC50 : 37.1 µMol/L |
| dbacp04348 | Lytic | KLlLKlLkkLLKlLKKK | Interleukin-4 receptor a (IL-4Ra) chain | Induction of apoptosis | WST-1 assay | SU.86.86 | Pancreatic cancer | IC50 : 28.0 µMol/L |
| dbacp04476 | Magainin 2 | GIGKFLHSAKKFGKAFVGEIMNS | African clawed frog | Membrane disruption | WST-1 assay | HeLa | Pancreatic cancer | IC50 : > 60 µM |
| dbacp05312 | Peptide 5 | fCYwO-CyLeu-Pen-TKKrPKPfQwFwL-CyLeu-KKLMYPTYLKKfQWAV-Aib-HL | Synthetic peptide of four designed analogs of vasoactive intestinal peptide, bombesin | Not specified | MTT/MTS assay | MiaPaCa.2 | Pancreatic cancer | 24.2 % inhibition of cell proliferation at 1 nM |
| dbacp05313 | Peptide 5 | fCYwO-CyLeu-Pen-TKKrPKPfQwFwL-CyLeu-KKLMYPTYLKKfQWAV-Aib-HL | Synthetic peptide of four designed analogs of vasoactive intestinal peptide, bombesin | Not specified | MTT/MTS assay | MiaPaCa.2 | Pancreatic cancer | 37.8 % inhibition of cell proliferation at 10 nM |
| dbacp05314 | Peptide 5 | fCYwO-CyLeu-Pen-TKKrPKPfQwFwL-CyLeu-KKLMYPTYLKKfQWAV-Aib-HL | Synthetic peptide of four designed analogs of vasoactive intestinal peptide, bombesin | Not specified | MTT/MTS assay | MiaPaCa.2 | Pancreatic cancer | 48.2 % inhibition of cell proliferation at 100 nM |
| dbacp05315 | Peptide 5 | fCYwO-CyLeu-Pen-TKKrPKPfQwFwL-CyLeu-KKLMYPTYLKKfQWAV-Aib-HL | Synthetic peptide of four designed analogs of vasoactive intestinal peptide, bombesin | Not specified | MTT/MTS assay | MiaPaCa.2 | Pancreatic cancer | 59.6 % inhibition of cell proliferation at 1 µM |
| dbacp05316 | Peptide 5 | fCYwO-CyLeu-Pen-TKKrPKPfQwFwL-CyLeu-KKLMYPTYLKKfQWAV-Aib-HL | Synthetic peptide of four designed analogs of vasoactive intestinal peptide, bombesin | Not specified | MTT/MTS assay | MiaPaCa.2 | Pancreatic cancer | 84.5 % inhibition of cell proliferation at 10 µM |
| dbacp05328 | Peptide 5 | fCYwO-CyLeu-Pen-TKKrPKPfQwFwL-CyLeu-KKLMYPTYLKKfQWAV-Aib-HL | Synthetic peptide of four designed analogs of vasoactive intestinal peptide, bombesin | Not specified | MTT/MTS assay | MiaPaCa.2 | Pancreatic cancer | ED50 : 0.210 µM |
| dbacp05587 | PNC-28 | ETFSDLWKLL | Ant | Membrane disruption | MTT/MTS assay | MiaPaCa.2 | Pancreatic cancer | Cytotoxicity : 80µg/ml |
| dbacp06023 | Sansalv amide A | NA | Synthetic Peptide | Apoptosis | Cell viability assay | S2-13 | Pancreatic cancer | EC50 : 7.5 µM |
| dbacp06201 | TAT-Bim (145-165) | RKKRRQ(orn)RRREIWIAQELRRIGDEFNAYYAR | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Panc-02 | Pancreatic cancer | Not found |
| dbacp06203 | TAT-CTMP4 | LDPKLMKEEQMSQAQLFTRSFDDGL | Not found | Inducing apoptosis | Not specified | Panc-1 | Pancreatic cancer | TAT-CTMP4 induced a dose-dependent increase in apoptosis as detected by %-TUNEL positive cells and %-active caspase-3 (% active caspase-3 ranged from 31.2 to 61.9 at the highest dose tested (10 µM). |
| dbacp06204 | TAT-CTMP4 | LDPKLMKEEQMSQAQLFTRSFDDGL | Not found | Inducing apoptosis | Not specified | Panc-02 | Pancreatic cancer | TAT-CTMP4 induced a dose-dependent increase in apoptosis as detected by %-TUNEL positive cells and %-active caspase-3 (% active caspase-3 ranged from 31.2 to 61.9 at the highest dose tested (10 µM). |
| dbacp06205 | TAT-CTMP4 | LDPKLMKEEQMSQAQLFTRSFDDGL | Not found | Inducing apoptosis | Not specified | AsPC-1 | Pancreatic cancer | TAT-CTMP4 induced a dose-dependent increase in apoptosis as detected by %-TUNEL positive cells and %-active caspase-3 (% active caspase-3 ranged from 31.2 to 61.9 at the highest dose tested (10 µM). |
| dbacp06206 | TAT-CTMP4 | LDPKLMKEEQMSQAQLFTRSFDDGL | Not found | Inducing apoptosis | Not specified | BxPC-3 | Pancreatic cancer | TAT-CTMP4 induced a dose-dependent increase in apoptosis as detected by %-TUNEL positive cells and %-active caspase-3 (% active caspase-3 ranged from 31.2 to 61.9 at the highest dose tested (10 µM). |
| dbacp06207 | TAT-CTMP4 | LDPKLMKEEQMSQAQLFTRSFDDGL | Not found | Inducing apoptosis | Not specified | CFPAC-1 | Pancreatic cancer | TAT-CTMP4 induced a dose-dependent increase in apoptosis as detected by %-TUNEL positive cells and %-active caspase-3 (% active caspase-3 ranged from 31.2 to 61.9 at the highest dose tested (10 µM). |
| dbacp06652 | LUNA18 | Not Available | Synthetic | Not available | CellTiter-Glo Cell Viability assay | MiaPaCa.2 | Pancreatic Cancer | IC50 = 1.4 ± 0.2 nmol/L |
| dbacp06883 | trichoderin A | MDA-P-Cha-Aib-Aib-IV-Aib-Aib-AMAE | Trichoderma sp. fungus, strain 05FI48 | Apoptosis inducing | PrestoBlue assay | BxPC-3 | Pancreatic Cancer | IC50 = 0.4 μM |
| dbacp06884 | trichoderin A | MDA-P-Cha-Aib-Aib-IV-Aib-Aib-AMAE | Trichoderma sp. fungus, strain 05FI48 | Apoptosis inducing | CyQUANT Direct assay | PANC-1 | Pancreatic Cancer | IC50 = 0.3 μM |
| dbacp06885 | trichoderin A analogue 4 | P-Cha-Aib-Aib-IV-Aib-Aib-AMAE | Trichoderin A | Apoptosis inducing | PrestoBlue assay | BxPC-3 | Pancreatic Cancer | IC50 = 0.4 μM |
| dbacp06886 | trichoderin A analogue 12 | P-Cha-Aib-Aib-IV-Aib-Aib-AMAE | Trichoderin A | Apoptosis inducing | PrestoBlue assay | BxPC-3 | Pancreatic Cancer | IC50 > 1 μM |
| dbacp06887 | trichoderin A analogue 13 | P-Cha-Aib-Aib-IV-Aib-Aib-AMAE | Trichoderin A | Apoptosis inducing | PrestoBlue assay | BxPC-3 | Pancreatic Cancer | IC50 > 1 μM |
| dbacp06888 | trichoderin A analogue 14 | P-Cha-Aib-Aib-IV-Aib-Aib-AMAE | Trichoderin A | Apoptosis inducing | PrestoBlue assay | BxPC-3 | Pancreatic Cancer | IC50 = 0.6 μM |
| dbacp06889 | trichoderin A analogue 15 | P-Cha-Aib-Aib-IV-Aib-Aib-AMAE | Trichoderin A | Apoptosis inducing | PrestoBlue assay | BxPC-3 | Pancreatic Cancer | IC50 = 0.5 μM |
| dbacp06890 | trichoderin A analogue 16 | P-Cha-Aib-Aib-IV-Aib-Aib-AMAE | Trichoderin A | Apoptosis inducing | PrestoBlue assay | BxPC-3 | Pancreatic Cancer | IC50 = 0.4 μM |
| dbacp06891 | trichoderin A analogue 17 | P-Cha-Aib-Aib-IV-Aib-Aib-AMAE | Trichoderin A | Apoptosis inducing | PrestoBlue assay | BxPC-3 | Pancreatic Cancer | IC50 = 0.4 μM |
| dbacp06892 | trichoderin A analogue 18 | P-Cha-Aib-Aib-IV-Aib-Aib-AMAE | Trichoderin A | Apoptosis inducing | PrestoBlue assay | BxPC-3 | Pancreatic Cancer | IC50 = 0.2 μM |
| dbacp06893 | trichoderin A analogue 4 | P-Cha-Aib-Aib-IV-Aib-Aib-AMAE | Trichoderin A | Apoptosis inducing | CyQUANT Direct assay | PANC-1 | Pancreatic Cancer | IC50 = 0.5 μM |
| dbacp06894 | trichoderin A analogue 12 | P-Cha-Aib-Aib-IV-Aib-Aib-AMAE | Trichoderin A | Apoptosis inducing | CyQUANT Direct assay | PANC-1 | Pancreatic Cancer | IC50 > 9 μM |
| dbacp06895 | trichoderin A analogue 13 | P-Cha-Aib-Aib-IV-Aib-Aib-AMAE | Trichoderin A | Apoptosis inducing | CyQUANT Direct assay | PANC-1 | Pancreatic Cancer | IC50 = 6.0 μM |
| dbacp06896 | trichoderin A analogue 14 | P-Cha-Aib-Aib-IV-Aib-Aib-AMAE | Trichoderin A | Apoptosis inducing | CyQUANT Direct assay | PANC-1 | Pancreatic Cancer | IC50 = 1.8 μM |
| dbacp06897 | trichoderin A analogue 15 | P-Cha-Aib-Aib-IV-Aib-Aib-AMAE | Trichoderin A | Apoptosis inducing | CyQUANT Direct assay | PANC-1 | Pancreatic Cancer | IC50 = 0.9 μM |
| dbacp06898 | trichoderin A analogue 16 | P-Cha-Aib-Aib-IV-Aib-Aib-AMAE | Trichoderin A | Apoptosis inducing | CyQUANT Direct assay | PANC-1 | Pancreatic Cancer | IC50 = 0.5 μM |
| dbacp06899 | trichoderin A analogue 17 | P-Cha-Aib-Aib-IV-Aib-Aib-AMAE | Trichoderin A | Apoptosis inducing | CyQUANT Direct assay | PANC-1 | Pancreatic Cancer | IC50 = 0.6 μM |
| dbacp06900 | trichoderin A analogue 18 | P-Cha-Aib-Aib-IV-Aib-Aib-AMAE | Trichoderin A | Apoptosis inducing | CyQUANT Direct assay | PANC-1 | Pancreatic Cancer | IC50 = 0.2 μM |
| dbacp06901 | trichoderin A analogue 19 | P-Cha-Aib-Aib-IV-Aib-Aib-AMAE | Trichoderin A | Apoptosis inducing | CyQUANT Direct assay | PANC-1 | Pancreatic Cancer | IC50 = 0.2 μM |
| dbacp06902 | trichoderin A analogue 19 | MDA-P-AHMOD-Aib-Aib-IV-Aib-Aib-AMAE | Trichoderin A | Apoptosis inducing | PrestoBlue assay | BxPC-3 | Pancreatic Cancer | IC50 = 0.1 μM |
| dbacp07027 | [G10a]-SHa | FLSGIVGMLaKLF | Analog of temporin SHa | Dendrimerization enhances stability, selectivity, anticancer efficacy | Resazurin dye assay | MiaPaCa.2 | Pancreatic Cancer | IC50 = 22.36 ± 6.07 µM |
| dbacp07034 | [G10a]2-SHa | FLSGIVGMLaKLFKFLKaLMFLSGIVG | Analog of temporin SHa | Dendrimerization enhances stability, selectivity, anticancer efficacy | Resazurin dye assay | MiaPaCa.2 | Pancreatic Cancer | IC50 = 8.71 ± 0.35 µM |
| dbacp07041 | [G10a]3-SHa | FLSGIVGMLaKLFFLSGIVGMLaKLFFLSGIVGMLaKLFKK | Analog of temporin SHa | Dendrimerization enhances stability, selectivity, anticancer efficacy | Resazurin dye assay | MiaPaCa.2 | Pancreatic Cancer | IC50 = 6.94 ± 0.27 µM |
| dbacp07047 | Jeff-[G10a]2-SHa | FLSGIVGMLaKLF-jeff-FLSGIVGMLaKLF | Analog of temporin SHa | Dendrimerization enhances stability, selectivity, anticancer efficacy | Resazurin dye assay | MiaPaCa.2 | Pancreatic Cancer | IC50 = 57.45 ± 6.03 µM |
| dbacp07853 | Dermaseptin-PT9 | GLWSKIKDAAKTAGKAALGFVNEMV | Phyllomedusa tarsius | Membrane disruption and cationic enhancement | MTT assay | PANC-1 | Pancreatic Cancer | IC50 = 28.95 µM |
| dbacp07858 | K8, 23-DPT9 | GLWSKIKKAAKTAGKAALGFVNKMV | Synthetic | Membrane disruption and cationic enhancement | MTT assay | PANC-1 | Pancreatic Cancer | IC50 = 11.17 µM |
| dbacp07881 | Nubein6.8 | LKCNQLIPPFWKTCPKGKNLCYKMTMRAAPMVPVKRGCIDVCPKSSLLIKYMCCNTDKCN | Naja nubiae | DNA damage and apoptosis induction | MTT assay | PANC-1 | Pancreatic Cancer | slight toxicity above 3.7 μM |
| dbacp07882 | 0Dap | GIKKWLHSAKKFGKKFVKKIZNS | Synthetic | Not Available | WST-1 assay | PANC-1 | Pancreatic Cancer | EC50 = 9.1±0.3 μM |
| dbacp07883 | 2Dap | GIKXWLHSAKKFGXKFVKKIZNS | Synthetic | Not Available | WST-1 assay | PANC-1 | Pancreatic Cancer | EC50 = 14.7±0.6 μM |
| dbacp07884 | 4Dap | GIKXWLHSAXKFGXKFVKXIZNS | Synthetic | Not Available | WST-1 assay | PANC-1 | Pancreatic Cancer | EC50 = 35.7±0.7 μM |
| dbacp07885 | 6Dap | GIKXWLHSAXXFGXKFVXXIZNS | Synthetic | Not Available | WST-1 assay | PANC-1 | Pancreatic Cancer | EC50 = 55.0±1.8 μM |
| dbacp07886 | 8Dap | GIXXWLHSAXXFGXXFVXXIZNS | Synthetic | Not Available | WST-1 assay | PANC-1 | Pancreatic Cancer | EC50 = 61.4±0.7 μM |
| dbacp08040 | Silk Fibroin peptide | Not Available | Silkworm Cocoons | SFP induces S-phase cell-cycle arrest | MTT assay | SW-1990 | Pancreatic Cancer | IC50 = 8.005 ± 1.34 mg/ml |
| dbacp08041 | Silk Fibroin peptide | Not Available | Silkworm Cocoons | SFP induces S-phase cell-cycle arrest | MTT assay | PANC-1 | Pancreatic Cancer | IC50 = 8.224 ± 1.43 mg/ml |
| dbacp08046 | R11-NLS-pep8 | RRRRRRRRRRRIKKKRKWEASALVCIRLVTSSKPRTVa | NKp44 derived synthetic peptide | NKp44-pep8 inhibits PCNA function | PrestoBlue assay | PANC-1 | Pancreatic Cancer | ED50 = 7.8 μM |
| dbacp08169 | Peptide - 1 | GF(A6c)G(A6c)KK(A6c)G(A6c)F(A6c)G(A6c)GKK(A6c)KKKK | Synthetic | Not Available | CellTiter-Glo assay | CPFAC-1 | Pancreatic Cancer | IC50 > 7.5 µM |
| dbacp08175 | Peptide - 1 | GF(A6c)G(A6c)KK(A6c)G(A6c)F(A6c)G(A6c)GKK(A6c)KKKK | Synthetic | Not Available | CellTiter-Glo assay | MiaPaCa.2 | Pancreatic Cancer | IC50 = 7.3 µM |
| dbacp08181 | Peptide - 2 | GF(A6c)G(A6c)R(A6c)G(A6c)F(A6c)G(A6c)GR(A6c)RRRR | Synthetic | Not Available | CellTiter-Glo assay | CPFAC-1 | Pancreatic Cancer | IC50 = 2.6 µM |
| dbacp08187 | Peptide - 2 | GF(A6c)G(A6c)R(A6c)G(A6c)F(A6c)G(A6c)GR(A6c)RRRR | Synthetic | Not Available | CellTiter-Glo assay | MiaPaCa.2 | Pancreatic Cancer | IC50 = 5.0 µM |
| dbacp08189 | Peptide - 3 | GF(A6c)G(A6c)Orn(A6c)G(A6c)F(A6c)G(A6c)GOrn(A6c)Orn-Orn- Orn- Orn | Synthetic | Not Available | CellTiter-Glo assay | CPFAC-1 | Pancreatic Cancer | IC50 = 5.9 µM |
| dbacp08195 | Peptide - 3 | GF(A6c)G(A6c)Orn(A6c)G(A6c)F(A6c)G(A6c)GOrn(A6c)Orn-Orn- Orn- Orn | Synthetic | Not Available | CellTiter-Glo assay | MiaPaCa.2 | Pancreatic Cancer | IC50 = 3.6 µM |
| dbacp08197 | Peptide - 4 | GF(A6c)G(A6c)Dab(A6c)G(A6c)F(A6c)G(A6c)GDab(A6c)Dab-Dab-Dab-Dab | Synthetic | Not Available | CellTiter-Glo assay | CPFAC-1 | Pancreatic Cancer | IC50 = 2.7 µM |
| dbacp08203 | Peptide - 4 | GF(A6c)G(A6c)Dab(A6c)G(A6c)F(A6c)G(A6c)GDab(A6c)Dab-Dab-Dab-Dab | Synthetic | Not Available | CellTiter-Glo assay | MiaPaCa.2 | Pancreatic Cancer | IC50 = 4.4 µM |
| dbacp08205 | Peptide - 6 | GF(A5c)G(A5c)K(A5c)G(A5c)F(A5c)G(A5c)GK(A5c)KKKK | Synthetic | Not Available | CellTiter-Glo assay | CPFAC-1 | Pancreatic Cancer | IC50 > 7.5 µM |
| dbacp08211 | Peptide - 6 | GF(A5c)G(A5c)K(A5c)G(A5c)F(A5c)G(A5c)GK(A5c)KKKK | Synthetic | Not Available | CellTiter-Glo assay | MiaPaCa.2 | Pancreatic Cancer | IC50 > 7.5 µM |
| dbacp08213 | Peptide - 7 | GF(A5c)G(A5c)R(A5c)G(A5c)F(A5c)G(A5c)GR(A5c)RRRR | Synthetic | Not Available | CellTiter-Glo assay | CPFAC-1 | Pancreatic Cancer | IC50 > 7.5 µM |
| dbacp08219 | Peptide - 7 | GF(A5c)G(A5c)R(A5c)G(A5c)F(A5c)G(A5c)GR(A5c)RRRR | Synthetic | Not Available | CellTiter-Glo assay | MiaPaCa.2 | Pancreatic Cancer | IC50 > 7.5 µM |
| dbacp08221 | Peptide - 8 | GF(A6c)G(Tic)K(A6c)G(Tic)F(A6c)G(Tic)GK(Tic)KKKK | Synthetic | Not Available | CellTiter-Glo assay | CPFAC-1 | Pancreatic Cancer | IC50 > 7.5 µM |
| dbacp08227 | Peptide - 8 | GF(A6c)G(Tic)K(A6c)G(Tic)F(A6c)G(Tic)GK(Tic)KKKK | Synthetic | Not Available | CellTiter-Glo assay | MiaPaCa.2 | Pancreatic Cancer | IC50 > 7.5 µM |
| dbacp08229 | Peptide - 9 | GF(A6c)G(Oic)K(A6c)G(Oic)F(A6c)G(Oic)GK(Oic)KKKK | Synthetic | Not Available | CellTiter-Glo assay | CPFAC-1 | Pancreatic Cancer | IC50 > 7.5 µM |
| dbacp08235 | Peptide - 9 | GF(A6c)G(Oic)K(A6c)G(Oic)F(A6c)G(Oic)GK(Oic)KKKK | Synthetic | Not Available | CellTiter-Glo assay | MiaPaCa.2 | Pancreatic Cancer | IC50 > 7.5 µM |
| dbacp08237 | Peptide - 10 | GF(A5c)G(A6c)K(A5c)G(A6c)F(A5c)G(A6c)GK(A5c)KKKK | Synthetic | Not Available | CellTiter-Glo assay | CPFAC-1 | Pancreatic Cancer | IC50 > 7.5 µM |
| dbacp08243 | Peptide - 10 | GF(A5c)G(A6c)K(A5c)G(A6c)F(A5c)G(A6c)GK(A5c)KKKK | Synthetic | Not Available | CellTiter-Glo assay | MiaPaCa.2 | Pancreatic Cancer | IC50 > 7.5 µM |
| dbacp08245 | Peptide - 11 | KKKKGF(A6c)G(A6c)K(A6c)G(A6c)F(A6c)G(A6c)GK(A6c) | Synthetic | Not Available | CellTiter-Glo assay | CPFAC-1 | Pancreatic Cancer | IC50 > 7.5 µM |
| dbacp08251 | Peptide - 11 | KKKKGF(A6c)G(A6c)K(A6c)G(A6c)F(A6c)G(A6c)GK(A6c) | Synthetic | Not Available | CellTiter-Glo assay | MiaPaCa.2 | Pancreatic Cancer | IC50 > 7.5 µM |
| dbacp08313 | P1C | YKSIEFC | Synthetic | Not Available | Cell Proliferation assay | BXPC-3 | Pancreatic Cancer | ~40% reduction in cell growth at 20 μM |
| dbacp08314 | P1A | YKSIEFC | Synthetic | Not Available | Cell Proliferation assay | BXPC-4 | Pancreatic Cancer | ~50% reduction in cell growth at 20 μM |
| dbacp08315 | P1B | YKSVEFC | Synthetic | Not Available | Cell Proliferation assay | BXPC-5 | Pancreatic Cancer | ~50% reduction in cell growth at 20 μM |
| dbacp08435 | Alpha-gliadin peptide p31-43 | LGQQQPFPPQQPY | Synthetic | Not Available | MTT assay | PANC-1 | Pancreatic Cancer | 26.2% growth inhibition at 70 μg/mL |